nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyl aminolevulinate—Burning sensation—Mitomycin—urinary bladder cancer	0.0313	0.0333	CcSEcCtD
Methyl aminolevulinate—Scab—Fluorouracil—urinary bladder cancer	0.0284	0.0303	CcSEcCtD
Methyl aminolevulinate—Stinging—Mitomycin—urinary bladder cancer	0.0268	0.0286	CcSEcCtD
Methyl aminolevulinate—Allergic contact dermatitis—Fluorouracil—urinary bladder cancer	0.0259	0.0276	CcSEcCtD
Methyl aminolevulinate—Ulcer—Mitomycin—urinary bladder cancer	0.023	0.0245	CcSEcCtD
Methyl aminolevulinate—Skin hyperpigmentation—Thiotepa—urinary bladder cancer	0.0184	0.0196	CcSEcCtD
Methyl aminolevulinate—Skin hyperpigmentation—Fluorouracil—urinary bladder cancer	0.0152	0.0162	CcSEcCtD
Methyl aminolevulinate—Blister—Fluorouracil—urinary bladder cancer	0.0126	0.0134	CcSEcCtD
Methyl aminolevulinate—Sensitisation—Epirubicin—urinary bladder cancer	0.0123	0.0131	CcSEcCtD
Methyl aminolevulinate—Discomfort—Valrubicin—urinary bladder cancer	0.0116	0.0124	CcSEcCtD
Methyl aminolevulinate—Sensitisation—Doxorubicin—urinary bladder cancer	0.0114	0.0122	CcSEcCtD
Methyl aminolevulinate—Stinging—Fluorouracil—urinary bladder cancer	0.0112	0.0119	CcSEcCtD
Methyl aminolevulinate—Dermatitis contact—Thiotepa—urinary bladder cancer	0.0108	0.0115	CcSEcCtD
Methyl aminolevulinate—Eye irritation—Fluorouracil—urinary bladder cancer	0.0106	0.0113	CcSEcCtD
Methyl aminolevulinate—Skin exfoliation—Thiotepa—urinary bladder cancer	0.0104	0.0111	CcSEcCtD
Methyl aminolevulinate—Infection—Carboplatin—urinary bladder cancer	0.0104	0.011	CcSEcCtD
Methyl aminolevulinate—Ulcer—Gemcitabine—urinary bladder cancer	0.00973	0.0104	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Interferon gamma signaling—MT2A—urinary bladder cancer	0.00964	0.158	CbGpPWpGaD
Methyl aminolevulinate—Ulcer—Fluorouracil—urinary bladder cancer	0.00956	0.0102	CcSEcCtD
Methyl aminolevulinate—Erythema—Mitomycin—urinary bladder cancer	0.00951	0.0101	CcSEcCtD
Methyl aminolevulinate—Ulcer—Cisplatin—urinary bladder cancer	0.00907	0.00966	CcSEcCtD
Methyl aminolevulinate—Dermatitis contact—Fluorouracil—urinary bladder cancer	0.00894	0.00952	CcSEcCtD
Methyl aminolevulinate—Pain—Carboplatin—urinary bladder cancer	0.00892	0.0095	CcSEcCtD
Methyl aminolevulinate—Skin exfoliation—Gemcitabine—urinary bladder cancer	0.00878	0.00936	CcSEcCtD
Methyl aminolevulinate—Ulcer—Etoposide—urinary bladder cancer	0.00831	0.00885	CcSEcCtD
Methyl aminolevulinate—Skin exfoliation—Cisplatin—urinary bladder cancer	0.00819	0.00872	CcSEcCtD
Methyl aminolevulinate—Asthenia—Valrubicin—urinary bladder cancer	0.00808	0.00861	CcSEcCtD
Methyl aminolevulinate—Discomfort—Mitomycin—urinary bladder cancer	0.008	0.00852	CcSEcCtD
Methyl aminolevulinate—Pruritus—Valrubicin—urinary bladder cancer	0.00797	0.00849	CcSEcCtD
Methyl aminolevulinate—Skin hyperpigmentation—Methotrexate—urinary bladder cancer	0.00791	0.00843	CcSEcCtD
Methyl aminolevulinate—Oedema—Mitomycin—urinary bladder cancer	0.00776	0.00826	CcSEcCtD
Methyl aminolevulinate—Skin exfoliation—Etoposide—urinary bladder cancer	0.0075	0.00799	CcSEcCtD
Methyl aminolevulinate—Dizziness—Valrubicin—urinary bladder cancer	0.00745	0.00793	CcSEcCtD
Methyl aminolevulinate—Swelling—Fluorouracil—urinary bladder cancer	0.00744	0.00793	CcSEcCtD
Methyl aminolevulinate—Skin hyperpigmentation—Epirubicin—urinary bladder cancer	0.0074	0.00789	CcSEcCtD
Methyl aminolevulinate—Rash—Valrubicin—urinary bladder cancer	0.0071	0.00756	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Valrubicin—urinary bladder cancer	0.0071	0.00756	CcSEcCtD
Methyl aminolevulinate—Headache—Valrubicin—urinary bladder cancer	0.00706	0.00752	CcSEcCtD
Methyl aminolevulinate—Dermatitis bullous—Gemcitabine—urinary bladder cancer	0.00699	0.00744	CcSEcCtD
Methyl aminolevulinate—Dermatitis bullous—Fluorouracil—urinary bladder cancer	0.00687	0.00732	CcSEcCtD
Methyl aminolevulinate—Skin hyperpigmentation—Doxorubicin—urinary bladder cancer	0.00685	0.0073	CcSEcCtD
Methyl aminolevulinate—Keratitis—Epirubicin—urinary bladder cancer	0.00679	0.00723	CcSEcCtD
Methyl aminolevulinate—Burning sensation—Methotrexate—urinary bladder cancer	0.00677	0.00721	CcSEcCtD
Methyl aminolevulinate—Nausea—Valrubicin—urinary bladder cancer	0.00669	0.00713	CcSEcCtD
Methyl aminolevulinate—Fatigue—Mitomycin—urinary bladder cancer	0.00669	0.00713	CcSEcCtD
Methyl aminolevulinate—FCGR1A—FCGR activation—SRC—urinary bladder cancer	0.00665	0.109	CbGpPWpGaD
Methyl aminolevulinate—Pain—Mitomycin—urinary bladder cancer	0.00664	0.00707	CcSEcCtD
Methyl aminolevulinate—Swelling—Etoposide—urinary bladder cancer	0.00646	0.00689	CcSEcCtD
Methyl aminolevulinate—Face oedema—Gemcitabine—urinary bladder cancer	0.00645	0.00687	CcSEcCtD
Methyl aminolevulinate—Burning sensation—Epirubicin—urinary bladder cancer	0.00634	0.00675	CcSEcCtD
Methyl aminolevulinate—Keratitis—Doxorubicin—urinary bladder cancer	0.00628	0.00669	CcSEcCtD
Methyl aminolevulinate—Blister—Epirubicin—urinary bladder cancer	0.00611	0.00651	CcSEcCtD
Methyl aminolevulinate—Skin ulcer—Methotrexate—urinary bladder cancer	0.00604	0.00644	CcSEcCtD
Methyl aminolevulinate—Face oedema—Cisplatin—urinary bladder cancer	0.00601	0.0064	CcSEcCtD
Methyl aminolevulinate—Burning sensation—Doxorubicin—urinary bladder cancer	0.00587	0.00625	CcSEcCtD
Methyl aminolevulinate—Skin ulcer—Epirubicin—urinary bladder cancer	0.00566	0.00602	CcSEcCtD
Methyl aminolevulinate—Blister—Doxorubicin—urinary bladder cancer	0.00565	0.00602	CcSEcCtD
Methyl aminolevulinate—Asthenia—Mitomycin—urinary bladder cancer	0.00557	0.00593	CcSEcCtD
Methyl aminolevulinate—Rash pustular—Epirubicin—urinary bladder cancer	0.00552	0.00588	CcSEcCtD
Methyl aminolevulinate—Stinging—Epirubicin—urinary bladder cancer	0.00544	0.00579	CcSEcCtD
Methyl aminolevulinate—Skin ulcer—Doxorubicin—urinary bladder cancer	0.00523	0.00557	CcSEcCtD
Methyl aminolevulinate—Photosensitivity reaction—Fluorouracil—urinary bladder cancer	0.00518	0.00552	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Thiotepa—urinary bladder cancer	0.00513	0.00547	CcSEcCtD
Methyl aminolevulinate—Dizziness—Mitomycin—urinary bladder cancer	0.00513	0.00547	CcSEcCtD
Methyl aminolevulinate—Rash pustular—Doxorubicin—urinary bladder cancer	0.00511	0.00544	CcSEcCtD
Methyl aminolevulinate—Stinging—Doxorubicin—urinary bladder cancer	0.00503	0.00536	CcSEcCtD
Methyl aminolevulinate—Ulcer—Methotrexate—urinary bladder cancer	0.00498	0.0053	CcSEcCtD
Methyl aminolevulinate—Rash—Mitomycin—urinary bladder cancer	0.00489	0.00521	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Mitomycin—urinary bladder cancer	0.00489	0.00521	CcSEcCtD
Methyl aminolevulinate—Headache—Mitomycin—urinary bladder cancer	0.00486	0.00518	CcSEcCtD
Methyl aminolevulinate—Erythema—Thiotepa—urinary bladder cancer	0.00478	0.00509	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Interferon Signaling—MT2A—urinary bladder cancer	0.00471	0.0771	CbGpPWpGaD
Methyl aminolevulinate—Ulcer—Epirubicin—urinary bladder cancer	0.00466	0.00496	CcSEcCtD
Methyl aminolevulinate—Nausea—Mitomycin—urinary bladder cancer	0.00461	0.00491	CcSEcCtD
Methyl aminolevulinate—Skin exfoliation—Methotrexate—urinary bladder cancer	0.00449	0.00479	CcSEcCtD
Methyl aminolevulinate—Dermatitis contact—Epirubicin—urinary bladder cancer	0.00435	0.00464	CcSEcCtD
Methyl aminolevulinate—Ulcer—Doxorubicin—urinary bladder cancer	0.00431	0.00459	CcSEcCtD
Methyl aminolevulinate—Skin exfoliation—Epirubicin—urinary bladder cancer	0.0042	0.00448	CcSEcCtD
Methyl aminolevulinate—Dermatitis contact—Doxorubicin—urinary bladder cancer	0.00403	0.00429	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Cisplatin—urinary bladder cancer	0.00402	0.00429	CcSEcCtD
Methyl aminolevulinate—Erythema—Gemcitabine—urinary bladder cancer	0.00402	0.00428	CcSEcCtD
Methyl aminolevulinate—Erythema—Fluorouracil—urinary bladder cancer	0.00395	0.00421	CcSEcCtD
Methyl aminolevulinate—Skin exfoliation—Doxorubicin—urinary bladder cancer	0.00389	0.00414	CcSEcCtD
Methyl aminolevulinate—Infection—Thiotepa—urinary bladder cancer	0.00388	0.00413	CcSEcCtD
Methyl aminolevulinate—Erythema—Cisplatin—urinary bladder cancer	0.00375	0.00399	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Etoposide—urinary bladder cancer	0.00369	0.00393	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Class I MHC mediated antigen processing & presentation—VHL—urinary bladder cancer	0.00364	0.0596	CbGpPWpGaD
Methyl aminolevulinate—Eczema—Epirubicin—urinary bladder cancer	0.00356	0.00379	CcSEcCtD
Methyl aminolevulinate—Eye pain—Epirubicin—urinary bladder cancer	0.00354	0.00377	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Thiotepa—urinary bladder cancer	0.0035	0.00373	CcSEcCtD
Methyl aminolevulinate—Discomfort—Gemcitabine—urinary bladder cancer	0.00338	0.0036	CcSEcCtD
Methyl aminolevulinate—Fatigue—Thiotepa—urinary bladder cancer	0.00336	0.00358	CcSEcCtD
Methyl aminolevulinate—Dermatitis bullous—Epirubicin—urinary bladder cancer	0.00334	0.00356	CcSEcCtD
Methyl aminolevulinate—Pain—Thiotepa—urinary bladder cancer	0.00334	0.00355	CcSEcCtD
Methyl aminolevulinate—Discomfort—Fluorouracil—urinary bladder cancer	0.00333	0.00354	CcSEcCtD
Methyl aminolevulinate—Eczema—Doxorubicin—urinary bladder cancer	0.00329	0.00351	CcSEcCtD
Methyl aminolevulinate—Oedema—Gemcitabine—urinary bladder cancer	0.00328	0.0035	CcSEcCtD
Methyl aminolevulinate—Eye pain—Doxorubicin—urinary bladder cancer	0.00328	0.00349	CcSEcCtD
Methyl aminolevulinate—Infection—Gemcitabine—urinary bladder cancer	0.00326	0.00347	CcSEcCtD
Methyl aminolevulinate—Oedema—Fluorouracil—urinary bladder cancer	0.00323	0.00344	CcSEcCtD
Methyl aminolevulinate—Infection—Fluorouracil—urinary bladder cancer	0.00321	0.00342	CcSEcCtD
Methyl aminolevulinate—Discomfort—Cisplatin—urinary bladder cancer	0.00315	0.00336	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—MT2A—urinary bladder cancer	0.00315	0.0515	CbGpPWpGaD
Methyl aminolevulinate—Urticaria—Thiotepa—urinary bladder cancer	0.0031	0.0033	CcSEcCtD
Methyl aminolevulinate—Dermatitis bullous—Doxorubicin—urinary bladder cancer	0.00309	0.0033	CcSEcCtD
Methyl aminolevulinate—Face oedema—Epirubicin—urinary bladder cancer	0.00309	0.00329	CcSEcCtD
Methyl aminolevulinate—Oedema—Cisplatin—urinary bladder cancer	0.00306	0.00326	CcSEcCtD
Methyl aminolevulinate—Infection—Cisplatin—urinary bladder cancer	0.00304	0.00324	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Gemcitabine—urinary bladder cancer	0.00295	0.00314	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Fluorouracil—urinary bladder cancer	0.0029	0.00309	CcSEcCtD
Methyl aminolevulinate—Discomfort—Etoposide—urinary bladder cancer	0.00289	0.00308	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00287	0.00306	CcSEcCtD
Methyl aminolevulinate—Face oedema—Doxorubicin—urinary bladder cancer	0.00286	0.00304	CcSEcCtD
Methyl aminolevulinate—Fatigue—Gemcitabine—urinary bladder cancer	0.00283	0.00301	CcSEcCtD
Methyl aminolevulinate—Pain—Gemcitabine—urinary bladder cancer	0.00281	0.00299	CcSEcCtD
Methyl aminolevulinate—Asthenia—Thiotepa—urinary bladder cancer	0.0028	0.00298	CcSEcCtD
Methyl aminolevulinate—Infection—Etoposide—urinary bladder cancer	0.00278	0.00297	CcSEcCtD
Methyl aminolevulinate—Pruritus—Thiotepa—urinary bladder cancer	0.00276	0.00294	CcSEcCtD
Methyl aminolevulinate—Pain—Fluorouracil—urinary bladder cancer	0.00276	0.00294	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Cisplatin—urinary bladder cancer	0.00275	0.00293	CcSEcCtD
Methyl aminolevulinate—Photosensitivity reaction—Methotrexate—urinary bladder cancer	0.00269	0.00287	CcSEcCtD
Methyl aminolevulinate—Pain—Cisplatin—urinary bladder cancer	0.00262	0.00279	CcSEcCtD
Methyl aminolevulinate—Dizziness—Thiotepa—urinary bladder cancer	0.00258	0.00275	CcSEcCtD
Methyl aminolevulinate—Urticaria—Fluorouracil—urinary bladder cancer	0.00256	0.00273	CcSEcCtD
Methyl aminolevulinate—Photosensitivity reaction—Epirubicin—urinary bladder cancer	0.00252	0.00269	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Etoposide—urinary bladder cancer	0.00252	0.00268	CcSEcCtD
Methyl aminolevulinate—Rash—Thiotepa—urinary bladder cancer	0.00246	0.00262	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Thiotepa—urinary bladder cancer	0.00246	0.00262	CcSEcCtD
Methyl aminolevulinate—Headache—Thiotepa—urinary bladder cancer	0.00244	0.0026	CcSEcCtD
Methyl aminolevulinate—Fatigue—Etoposide—urinary bladder cancer	0.00242	0.00257	CcSEcCtD
Methyl aminolevulinate—Pain—Etoposide—urinary bladder cancer	0.0024	0.00255	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.00238	0.00253	CcSEcCtD
Methyl aminolevulinate—Asthenia—Gemcitabine—urinary bladder cancer	0.00236	0.00251	CcSEcCtD
Methyl aminolevulinate—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.00233	0.00249	CcSEcCtD
Methyl aminolevulinate—Pruritus—Gemcitabine—urinary bladder cancer	0.00232	0.00247	CcSEcCtD
Methyl aminolevulinate—Nausea—Thiotepa—urinary bladder cancer	0.00232	0.00247	CcSEcCtD
Methyl aminolevulinate—Pruritus—Fluorouracil—urinary bladder cancer	0.00228	0.00243	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00225	0.0024	CcSEcCtD
Methyl aminolevulinate—Urticaria—Etoposide—urinary bladder cancer	0.00223	0.00237	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Methotrexate—urinary bladder cancer	0.00221	0.00235	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Interferon Signaling—IFNA2—urinary bladder cancer	0.00221	0.0361	CbGpPWpGaD
Methyl aminolevulinate—Asthenia—Cisplatin—urinary bladder cancer	0.0022	0.00234	CcSEcCtD
Methyl aminolevulinate—Dizziness—Fluorouracil—urinary bladder cancer	0.00213	0.00227	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Class I MHC mediated antigen processing & presentation—RBX1—urinary bladder cancer	0.00209	0.0342	CbGpPWpGaD
Methyl aminolevulinate—Rash—Gemcitabine—urinary bladder cancer	0.00207	0.0022	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Gemcitabine—urinary bladder cancer	0.00207	0.0022	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Epirubicin—urinary bladder cancer	0.00207	0.0022	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Etoposide—urinary bladder cancer	0.00207	0.0022	CcSEcCtD
Methyl aminolevulinate—Erythema—Methotrexate—urinary bladder cancer	0.00206	0.00219	CcSEcCtD
Methyl aminolevulinate—Headache—Gemcitabine—urinary bladder cancer	0.00206	0.00219	CcSEcCtD
Methyl aminolevulinate—Rash—Fluorouracil—urinary bladder cancer	0.00203	0.00217	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Fluorouracil—urinary bladder cancer	0.00203	0.00217	CcSEcCtD
Methyl aminolevulinate—Headache—Fluorouracil—urinary bladder cancer	0.00202	0.00215	CcSEcCtD
Methyl aminolevulinate—Asthenia—Etoposide—urinary bladder cancer	0.00201	0.00214	CcSEcCtD
Methyl aminolevulinate—Pruritus—Etoposide—urinary bladder cancer	0.00198	0.00211	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—PRSS3—urinary bladder cancer	0.00197	0.0322	CbGpPWpGaD
Methyl aminolevulinate—Nausea—Gemcitabine—urinary bladder cancer	0.00195	0.00208	CcSEcCtD
Methyl aminolevulinate—Rash—Cisplatin—urinary bladder cancer	0.00193	0.00205	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Cisplatin—urinary bladder cancer	0.00193	0.00205	CcSEcCtD
Methyl aminolevulinate—Erythema—Epirubicin—urinary bladder cancer	0.00193	0.00205	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—RBX1—urinary bladder cancer	0.00192	0.0314	CbGpPWpGaD
Methyl aminolevulinate—Nausea—Fluorouracil—urinary bladder cancer	0.00192	0.00204	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Doxorubicin—urinary bladder cancer	0.00191	0.00204	CcSEcCtD
Methyl aminolevulinate—Dizziness—Etoposide—urinary bladder cancer	0.00185	0.00197	CcSEcCtD
Methyl aminolevulinate—Nausea—Cisplatin—urinary bladder cancer	0.00182	0.00194	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—VHL—urinary bladder cancer	0.0018	0.0295	CbGpPWpGaD
Methyl aminolevulinate—Erythema—Doxorubicin—urinary bladder cancer	0.00178	0.0019	CcSEcCtD
Methyl aminolevulinate—Rash—Etoposide—urinary bladder cancer	0.00177	0.00188	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Etoposide—urinary bladder cancer	0.00177	0.00188	CcSEcCtD
Methyl aminolevulinate—Headache—Etoposide—urinary bladder cancer	0.00176	0.00187	CcSEcCtD
Methyl aminolevulinate—Discomfort—Methotrexate—urinary bladder cancer	0.00173	0.00184	CcSEcCtD
Methyl aminolevulinate—Infection—Methotrexate—urinary bladder cancer	0.00167	0.00178	CcSEcCtD
Methyl aminolevulinate—Nausea—Etoposide—urinary bladder cancer	0.00166	0.00177	CcSEcCtD
Methyl aminolevulinate—Discomfort—Epirubicin—urinary bladder cancer	0.00162	0.00172	CcSEcCtD
Methyl aminolevulinate—Oedema—Epirubicin—urinary bladder cancer	0.00157	0.00167	CcSEcCtD
Methyl aminolevulinate—Infection—Epirubicin—urinary bladder cancer	0.00156	0.00166	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Fcgamma receptor (FCGR) dependent phagocytosis—SRC—urinary bladder cancer	0.00154	0.0252	CbGpPWpGaD
Methyl aminolevulinate—Paraesthesia—Methotrexate—urinary bladder cancer	0.00151	0.00161	CcSEcCtD
Methyl aminolevulinate—Discomfort—Doxorubicin—urinary bladder cancer	0.0015	0.0016	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—IFNA2—urinary bladder cancer	0.00147	0.0241	CbGpPWpGaD
Methyl aminolevulinate—Oedema—Doxorubicin—urinary bladder cancer	0.00145	0.00155	CcSEcCtD
Methyl aminolevulinate—Fatigue—Methotrexate—urinary bladder cancer	0.00145	0.00154	CcSEcCtD
Methyl aminolevulinate—Infection—Doxorubicin—urinary bladder cancer	0.00144	0.00154	CcSEcCtD
Methyl aminolevulinate—Pain—Methotrexate—urinary bladder cancer	0.00144	0.00153	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Epirubicin—urinary bladder cancer	0.00141	0.0015	CcSEcCtD
Methyl aminolevulinate—Fatigue—Epirubicin—urinary bladder cancer	0.00135	0.00144	CcSEcCtD
Methyl aminolevulinate—Pain—Epirubicin—urinary bladder cancer	0.00134	0.00143	CcSEcCtD
Methyl aminolevulinate—Urticaria—Methotrexate—urinary bladder cancer	0.00133	0.00142	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—BIRC3—urinary bladder cancer	0.00131	0.0215	CbGpPWpGaD
Methyl aminolevulinate—Paraesthesia—Doxorubicin—urinary bladder cancer	0.00131	0.00139	CcSEcCtD
Methyl aminolevulinate—Fatigue—Doxorubicin—urinary bladder cancer	0.00125	0.00134	CcSEcCtD
Methyl aminolevulinate—Urticaria—Epirubicin—urinary bladder cancer	0.00125	0.00133	CcSEcCtD
Methyl aminolevulinate—Pain—Doxorubicin—urinary bladder cancer	0.00124	0.00132	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Methotrexate—urinary bladder cancer	0.00124	0.00132	CcSEcCtD
Methyl aminolevulinate—Asthenia—Methotrexate—urinary bladder cancer	0.0012	0.00128	CcSEcCtD
Methyl aminolevulinate—Pruritus—Methotrexate—urinary bladder cancer	0.00119	0.00127	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Epirubicin—urinary bladder cancer	0.00116	0.00123	CcSEcCtD
Methyl aminolevulinate—Urticaria—Doxorubicin—urinary bladder cancer	0.00115	0.00123	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—PRSS3—urinary bladder cancer	0.00115	0.0187	CbGpPWpGaD
Methyl aminolevulinate—Asthenia—Epirubicin—urinary bladder cancer	0.00113	0.0012	CcSEcCtD
Methyl aminolevulinate—Pruritus—Epirubicin—urinary bladder cancer	0.00111	0.00118	CcSEcCtD
Methyl aminolevulinate—Dizziness—Methotrexate—urinary bladder cancer	0.00111	0.00118	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—VHL—urinary bladder cancer	0.00109	0.0179	CbGpPWpGaD
Methyl aminolevulinate—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.00107	0.00114	CcSEcCtD
Methyl aminolevulinate—Rash—Methotrexate—urinary bladder cancer	0.00106	0.00113	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Methotrexate—urinary bladder cancer	0.00106	0.00113	CcSEcCtD
Methyl aminolevulinate—Headache—Methotrexate—urinary bladder cancer	0.00105	0.00112	CcSEcCtD
Methyl aminolevulinate—Asthenia—Doxorubicin—urinary bladder cancer	0.00104	0.00111	CcSEcCtD
Methyl aminolevulinate—Dizziness—Epirubicin—urinary bladder cancer	0.00104	0.00111	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—RBX1—urinary bladder cancer	0.00103	0.0169	CbGpPWpGaD
Methyl aminolevulinate—Pruritus—Doxorubicin—urinary bladder cancer	0.00103	0.0011	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—MT2A—urinary bladder cancer	0.00103	0.0168	CbGpPWpGaD
Methyl aminolevulinate—Nausea—Methotrexate—urinary bladder cancer	0.000997	0.00106	CcSEcCtD
Methyl aminolevulinate—Rash—Epirubicin—urinary bladder cancer	0.000991	0.00106	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Epirubicin—urinary bladder cancer	0.00099	0.00105	CcSEcCtD
Methyl aminolevulinate—Headache—Epirubicin—urinary bladder cancer	0.000984	0.00105	CcSEcCtD
Methyl aminolevulinate—Dizziness—Doxorubicin—urinary bladder cancer	0.000961	0.00102	CcSEcCtD
Methyl aminolevulinate—Nausea—Epirubicin—urinary bladder cancer	0.000933	0.000994	CcSEcCtD
Methyl aminolevulinate—Rash—Doxorubicin—urinary bladder cancer	0.000917	0.000976	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Doxorubicin—urinary bladder cancer	0.000916	0.000975	CcSEcCtD
Methyl aminolevulinate—Headache—Doxorubicin—urinary bladder cancer	0.000911	0.00097	CcSEcCtD
Methyl aminolevulinate—Nausea—Doxorubicin—urinary bladder cancer	0.000864	0.00092	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—IFNA2—urinary bladder cancer	0.000826	0.0135	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—S100B—urinary bladder cancer	0.000781	0.0128	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—BIRC3—urinary bladder cancer	0.000764	0.0125	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—IL2—urinary bladder cancer	0.000654	0.0107	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—RBX1—urinary bladder cancer	0.000628	0.0103	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—FGFR3—urinary bladder cancer	0.000568	0.00929	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—FGFR3—urinary bladder cancer	0.000545	0.00892	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—CREBBP—urinary bladder cancer	0.000483	0.00791	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—IFNA2—urinary bladder cancer	0.000481	0.00787	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—KRAS—urinary bladder cancer	0.000473	0.00773	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—CDH1—urinary bladder cancer	0.000461	0.00754	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—S100B—urinary bladder cancer	0.000455	0.00744	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—ERBB2—urinary bladder cancer	0.000405	0.00662	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—HRAS—urinary bladder cancer	0.000402	0.00657	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—ERBB2—urinary bladder cancer	0.000389	0.00636	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—CDKN1A—urinary bladder cancer	0.000346	0.00566	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—PTEN—urinary bladder cancer	0.000345	0.00565	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—CDKN1A—urinary bladder cancer	0.000332	0.00544	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—PTEN—urinary bladder cancer	0.000331	0.00542	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—FGFR3—urinary bladder cancer	0.000331	0.00541	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—EP300—urinary bladder cancer	0.000329	0.00539	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—SRC—urinary bladder cancer	0.00032	0.00524	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—SRC—urinary bladder cancer	0.000307	0.00503	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—CREBBP—urinary bladder cancer	0.000282	0.00461	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—EGFR—urinary bladder cancer	0.000281	0.00459	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—CDH1—urinary bladder cancer	0.000279	0.00457	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—EGFR—urinary bladder cancer	0.000269	0.00441	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—KRAS—urinary bladder cancer	0.000265	0.00434	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—KRAS—urinary bladder cancer	0.000255	0.00417	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—ERBB2—urinary bladder cancer	0.000236	0.00386	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—HRAS—urinary bladder cancer	0.000225	0.00369	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—HRAS—urinary bladder cancer	0.000216	0.00354	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—IL2—urinary bladder cancer	0.000214	0.0035	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—CDKN1A—urinary bladder cancer	0.000202	0.0033	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—PTEN—urinary bladder cancer	0.000201	0.00329	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—EP300—urinary bladder cancer	0.000192	0.00314	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—SRC—urinary bladder cancer	0.000186	0.00305	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—EGFR—urinary bladder cancer	0.000163	0.00267	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—KRAS—urinary bladder cancer	0.000154	0.00253	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—HRAS—urinary bladder cancer	0.000131	0.00215	CbGpPWpGaD
